Zomanex Overview
- Founded
- 2006
- Status
- Private
- Latest Deal Type
- Early Stage VC
- Investors
- 1
Zomanex General Information
Description
Operator of a drug formulation development company intended to transform intravenous, injectable, and oral therapeutics into novel orally delivered medicines. The company's products help in the conversion of intravenous or injectable xenobiotics into orally deliverable substances, as well as make it easy for hydrophobic compounds to be absorbed in the small intestine, enabling physicians to permit oral dosing of pharmaceutical compounds that have previously been administered intravenously or by injection.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
- Three Bentall Centre, P.O. Box 49314
- Suite 2600, 595 Burrard Street
- Vancouver, British Columbia V7X 1L3
- Canada
+1 (604) 000-0000
Zomanex Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | Completed | Generating Revenue |
Zomanex Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Paul Drohan | Chief Executive Officer | ||
| Curtis Spilburg Ph.D | Chief Scientific Officer | ||
| Doris Schnelle | Director, Business Development |
Zomanex Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Peter Craddock | Shoreline Venture Management | Board Member | 000 0000 |
Zomanex Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Shoreline Venture Management | Venture Capital | Minority | 000 0000 | 000000 0 |